There are 2789 resources available
1042P - Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts)
Presenter: Ines Pires da Silva
Session: ePoster Display
942P - The role of intraoperative electron radiotherapy in centrally located hepatocellular carcinomas treated with narrow-margin (<1 cm) hepatectomy: A prospective, phase II study
Presenter: Liming Wang
Session: ePoster Display
Resources:
Abstract
943P - Long-term outcome of the oldest-old patients (85 years or older) underwent proton beam therapy for hepatocellular carcinoma
Presenter: Takashi Iizumi
Session: ePoster Display
944P - Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial
Presenter: Xinrong Yang
Session: ePoster Display
946P - Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)
Presenter: Tian-Qi Zhang
Session: ePoster Display
1047P - Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
Presenter: Prachi Bhave
Session: ePoster Display
1048P - Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
Presenter: Jeeyun Lee
Session: ePoster Display
1049P - Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI)
Presenter: Florentia Dimitriou
Session: ePoster Display
1050P - Outcome and impact of immune related adverse events in patients with advanced melanoma treated with checkpoint inhibitors
Presenter: Arkhjamil Angeles
Session: ePoster Display